Use of enoxaparin in patients with chronic kidney disease: safety considerations.
Brophy
Donald F
DF
Department of Pharmacy, Virginia Commonwealth University/Medical College of Virginia Campus, Richmond, Virginia 23298-0533, USA. DBrophy@vcu.edu
Sica
Domenic A
DA
D000818:Animals; D000925:Anticoagulants / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D017984:Enoxaparin / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006470:Hemorrhage / Q000150:complications* / Q000517:prevention & control*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood / Q000150:complications*
D000925:Anticoagulants; D017984:Enoxaparin